Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 4/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | GLP1R | P43220 | 8/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | CASP2 | P42575 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26032001 | 0.91 | LPAR1 (0.44) | FAAHEPHX1GLP1RDNM1LPAR1 | |
| SCHEMBL25067300 | 0.90 | FAAH (0.59) | FAAHGLP1RDNM1LPAR1LPAR2 | |
| SCHEMBL21575544 | 0.89 | HPGD (0.43) | GLP1R | |
| SCHEMBL23879753 | 0.88 | MEN1 (0.45) | EPHX1GLP1RCASP2 | |
| SCHEMBL26031999 | 0.88 | GLP1R (0.52) | FAAHGLP1RLPAR1 | |
| SCHEMBL5163458 | 0.87 | TLR2 (0.55) | FAAHEPHX1CASP2 | |
| SCHEMBL13811075 | 0.87 | FAAH (0.62) | FAAHGLP1RDNM1LPAR1LPAR2 | |
| SCHEMBL7646590 | 0.87 | FAAH (0.62) | FAAHGLP1RDNM1LPAR1LPAR2 | |
| SCHEMBL7650140 | 0.87 | FAAH (0.62) | FAAHGLP1RDNM1LPAR1LPAR2 | |
| SCHEMBL7647954 | 0.87 | FAAH (0.62) | FAAHGLP1RDNM1LPAR1LPAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-01-26 | — | — | US | disclosed |
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | FAAH 4341/4885EPHX1 2734/4885GLP1R 4362/4885 |
| US-20230028321-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, NUDT1 | FAAH 4162/4885EPHX1 2524/4885GLP1R 4143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.